STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its...
Hence then, the article about bioarctic s global license agreement with bristol myers squibb for pyroglutamate amyloid beta antibody program effective after antitrust clearance and closing was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing )
Also on site :
- LIVE: Watch friends and family cross the 2026 Chicago Marathon finish line
- In the 1940s, Howard Hughes bought the peak next to the Hollywood Sign to build a house for Ginger Rogers; in 2010 more than 100 acres of it became part of Griffith Park
- Gardeners Say You Can Still Plant These 8 Vegetables in November—With the Right Conditions for a Future Harvest